POS1508 PREVALENCE OF REMISSION ACCORDING TO PHYSICIAN AND PATIENT AND LEVEL OF AGREEMENT IN A REAL-WORLD MULTICENTER LUPUS REGISTRY
Authors: J. Martínez-Barrio, I. Castrejon, J. M. Pego-Reigosa, M. Galindo-Izquierdo, E. Uriarte Isacelaya, E. Aurrecoechea, N. Mena-Vázquez, I. Altabás González, J. Rosas, S. Gomez-Sabater, M. Ibañez Barceló, V. Torrente Segarra, J. Narváez, C. Sanguesa, J. Calvet, M. Freire González, C. Moriano, C. L. Iñíguez, E. Tomero Muriel, A. Pérez Gómez, J. L. Andréu Sánchez, M. J. Garcia Villanueva, T. Cobo-Ibáñez, G. Bonilla, N. Lozano Rivas, L. Horcada, C. A. Montilla-Morales, F. J. Toyos Sáenz de Miera, L. Expósito, E. Ruiz Lucea, J. Eloy Oller, A. Pecondon-Español, R. Blanco, S. Machin, E. Salgado Perez, I. Carrión Barberà, R. Menor-Almagro, J. Calvo, A. Muñoz Jimenez, J. J. Fragío Gil, I. Rua-Figueroa
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Improvement on health-related quality of life (HRQoL) in patients with Systemic Lupus Erythematosus (SLE) remains a challenge. There is limited data on the level of agreement on remission according to physician and patient and remission impact on HRQoL and long-term outcomes. <h3>Objectives</h3> To investigate the prevalence and level of agreement between remission according to physician and patient criteria and to evaluate the impact of remission on HRQoL in patients with SLE. <h3>Methods</h3> Prospective study of patients included in RELESSER-PROS, a multicenter register of SLE patients. Protocol of the register has been previously described [1]. Remission according to physician was defined in agreement with DORIS 2021 criteria: clinical SLEDAI 0, physician global assessment ≤2 on a 0-10 Likert scale (equivalent to ≤0.5 on a 0-3 scale), stable low-dose prednisone (≤5mg) and stable immunosuppressive/ biologic agents if remission on therapy. Remission according to patient was defined as SLAQ (Systemic Lupus Activity Questionnaire) question 1 with no flare in the last 3 months (score 0). Patients were classified in three groups according to remission status by DORIS, SLAQ or both. Level of agreement was assessed using kappa statistics. Acceptable level of agreement was considered if kappa &gt;0.60. <h3>Results</h3> 1102 patients, with a follow-up of at least 2 years (data from 3 visits available) were included in this analysis. Patient characteristics according remission status at baseline are presented in the Table 1. At baseline, remission by DORIS was present in 16.1%, by SLAQ 16.7% and 2.45% by both. Remission by DORIS was more frequent among patients with higher education, on immunosuppressant and biological therapy and patients with history of hospitalization; remission by SLAQ was more frequent among women, obese patients, and those on antimalarials (p&lt;0.05). Symptoms reported in patients who considered themselves in remission were mainly cutaneous and articular (53.3%). Mean SLEDAI in patients on remission by SLAQ was 3.28 (3.78). Patients in remission by DORIS had significantly better results in patient reported outcomes (PRO) measured by EQ-5D and LIT (p&lt;0.05). Level of agreement in remission according to physician and patient was 78.04% (k=0.061) at baseline, 63.39% (k=0.039), and 62.73% (k=0.099) in year 2 and 5 respectively. Kappa level of agreement was low. <h3>Conclusion</h3> Our results reflect low level of agreement between physician and patients in terms of remission status with increasing disagreement in the follow-up. Patients in remission by DORIS shows better results in EQ-5D and LIT. <h3>Reference</h3> [1] Rúa-Figueroa I, et al. Reumatol Clin. 2014;10(1):17-24. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.